The cells that line the mucosa of the human gastrointestinal tract (GI, that is, oral cavity, oesophagus, stomach, small intestine, large intestine, and rectum) are constantly challenged by adverse micro-environmental factors, such as different pH, enzymes, and bacterial flora. With exception of the oral cavity, these microenvironments also contain remnant cocktails of secreted enzymes and bacteria from upper organs along the tract. The density of the GI bacteria varies, from 10 3/mL near the gastric outlet, to 10 10/mL at the ileocecal valve, to 10 11 to 10 12/mL in the colon. The total microbial population ( ca. 10 14) exceeds the total number of cells in the tract. It is, therefore, remarkable that despite the prima facie inauspicious mixture of harmful secretions and bacteria, the normal GI mucosa retains a healthy state of cell renewal. To counteract the hostile microenvironment, the GI epithelia react by speeding cell exfoliation (the GI mucosa has a turnover time of two to three days), by increasing peristalsis, by eliminating bacteria through secretion of plasma cell-immunoglobulins and by increasing production of natural antibacterial compounds, such as defensin-5 and lysozyme. Only recently, lysozyme was found up-regulated in Barrett’s oesophagitis, chronic gastritis, gluten-induced atrophic duodenitis (coeliac disease), collagenous colitis, lymphocytic colitis, and Crohn’s colitis. This up-regulation is a response directed to the special types of bacteria recently detected in these diseases. The aim of lysozyme up-regulation is to protect individual mucosal segments to chronic inflammation. The molecular mechanisms connected to the crosstalk between the intraluminal bacterial flora and the production of lysozyme released by the GI mucosae, are discussed. Bacterial resistance continues to exhaust our supply of commercial antibiotics. The potential use of lysozyme to treat infectious diseases is receiving much attention.
References
[1]
Kaper, J.B.; Sperandio, V. Bacterial cell-to-cell signaling in the gastrointestinal tract. Infect. Immun. 2005, 73, 3197–3209, doi:10.1128/IAI.73.6.3197-3209.2005.
[2]
Dominguez-Bello, M.G.; Blaser, M.J.; Ley, R.E.; Knight, R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 2011, 140, 1713–1719, doi:10.1053/j.gastro.2011.02.011.
[3]
Fleming, A. On a remarkable bacteriolytic element found in tissues and secretions. Proc. R. Soc. Sect. B 1922, 93, 306–312, doi:10.1098/rspb.1922.0023.
[4]
Yoshimura, K.; Toibana, A.; Nakahama, K. Human lysozyme: Sequencing of a cDNA, and expression and secretion by Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 1988, 150, 794–801, doi:10.1016/0006-291X(88)90461-5.
[5]
Peters, C.; Kruse, U.; Pollwein, R.; Grzeschik, K.; Sippel, T. The human lysozyme gene. Sequence organization and chromosomal localization. Eur. J. Biochem. 1989, 182, 507–512, doi:10.1111/j.1432-1033.1989.tb14857.x.
[6]
Sahoo, N.R.; Kumar, P.; Bhusan, B.; Bhattacharya, T.K.; Dayal, S.; Sahoo, M. Lysozyme in livestock: A guide to selection for disease resistance: A review. J. Anim. Sci. Adv. 2012, 2, 347–360.
[7]
Rubio, C.A.; L？rinc, E. Lysozyme is up-regulated in Barrett’s mucosa. Histopathology 2011, 58, 796–799, doi:10.1111/j.1365-2559.2011.03830.x.
[8]
Rubio, C.A.; Befrits, R. Increased lysozyme expression in gastric biopsies with intestinal metaplasia and pseudopyloric metaplasia. Int. J. Clin. Exp. Med. 2009, 2, 248–253.
[9]
Rubio, C.A. Lysozyme expression in microscopic colitis. J. Clin. Pathol. 2011, 64, 510–515, doi:10.1136/jcp.2010.086850.
[10]
Rubio, C.A. Lysozyme-rich mucus metaplasia in duodenal crypts supersedes Paneth cells in celiac disease. Virchows Arch. 2011, 459, 339–346, doi:10.1007/s00428-011-1129-3.
[11]
Appelman, H.D.; Umar, A.; Orlando, R.C.; Sontag, S.J.; Nandurkar, S.; el-Zimaity, H.; Lanas, A.; Parise, P.; Lambert, R.; Shields, H.M. Barrett’s esophagus: Natural history. Ann. N. Y. Acad. Sci. 2011, 1232, 292–308, doi:10.1111/j.1749-6632.2011.06057.x.
[12]
Rubio, C.A.; Dick, E.J.; Schlabritz-Loutsevitch, N.E.; Orrego, A.; Hubbard, G.B. The columnar-lined mucosa at the gastroesophageal junction in non-human primates. Int. J. Clin. Exp. Pathol. 2009, 2, 481–488.
[13]
Rubio, C.A.; Nilsson, J.R.; Owston, M.; Dick, E.J., Jr. The length of the Barrett's mucosa in baboons, revisited. Anticancer Res. 2012, 32, 3115–3118.
[14]
Spechler, S.; Goyal, R.K. Barrett’s esophagus. N. Engl. J. Med. 1986, 315, 362–367, doi:10.1056/NEJM198608073150605.
[15]
Sampliner, R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1998, 93, 1028–1032, doi:10.1111/j.1572-0241.1998.00362.x.
[16]
Playford, R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett’s oesophagus. Gut 2006, 55, 442–444, doi:10.1136/gut.2005.083600.
[17]
Fiocca, R.; Mastracci, L.; Milione, M.; Parente, P.; Savarino, V. Gruppo Italiano Patologi Apparato Digerente (GIPAD) and Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Microscopic esophagitis and Barrett’s esophagus: The histology report. Dig. Liver Dis. 2011, 43, S319–S330, doi:10.1016/S1590-8658(11)60588-4.
[18]
Takubo, K.; Vieth, M.; Aida, J.; Sawabe, M.; Kumagai, Y.; Hoshihara, Y.; Arai, T. Differences in the definitions used for esophageal and gastric diseases in different countries: Endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion 2009, 80, 248–257, doi:10.1159/000235923.
[19]
Waldum, H.L.; Hauso, ？.; Sandvik, A.K. PPI-induced hypergastrinaemia and Barrett’s mucosa: The fog thickens. Gut 2010, 59, 1157–1158, doi:10.1136/gut.2010.213173.
[20]
Yang, L.; Lu, X.; Nossa, C.W.; Francois, F.; Peek, R.M.; Pei, Z.; Yang, L.; Lu, X.; Nossa, C.W.; Francois, F.; et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009, 137, 588–597, doi:10.1053/j.gastro.2009.04.046.
[21]
Pei, Z.; Yang, L.; Peek, R.M., Jr.; Levine, S.M.; Pride, D.T.; Blaser, M.J. Bacterial biota in reflux esophagitis and Barrett’s esophagus. World J. Gastroenterol. 2005, 11, 7277–7283.
[22]
Macfarlane, S.; Furrie, E.; Macfarlane, G.; Dillon, J. Microbial colonization of the upper gastrointestinal tract in patients with Barrett’s esophagus. Clin. Infect. Dis. 2007, 45, 29–38, doi:10.1086/518578.
[23]
Liu, N.; Ando, T.; Ishiguro, K.; Maeda, O.; Watanabe, O.; Funasaka, K.; Nakamura, M.; Miyahara, R.; Ohmiya, N.; Goto, H. Characterization of bacterial biota in the distal esophagus of Japanese patients with reflux esophagitis and Barrett’s esophagus. BMC Infect. Dis. 2013, 13, 130–136, doi:10.1186/1471-2334-13-130.
[24]
Rubio, C.A. Lysozyme is up-regulated in columnar-lined Barrett’s mucosa: A possible natural defence mechanism against Barrett’s esophagus-associated pathogenic bacteria. Anticancer Res. 2012, 32, 5115–5119.
[25]
Sarosi, G.; Brown, G.; Jaiswal, K.; Feagins, L.A.; Lee, E.; Crook, T.W.; Souza, R.F.; Zou, Y.S.; Shay, J.W.; Spechler, S.J. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett’s esophagus. Dis. Esophagus 2008, 21, 43–50.
[26]
Rubio, C.A. Putative Stem Cells in Mucosas of the Esophago-Gastrointestinal TractChapter 10. In Stem Cell, Regenerative Medicine and Cancer; Singh, S.R., Ed.; Nova Science Publishers, Inc.: Haupauge, NY, USA, 2011; pp. 281–310.
[27]
Misiewicz, J.; Tygat, G.; Goodwin, C. The Sydney System: A new classification of gastritis. Work. Party Rep. 1990, 1, 10–11.
[28]
Cruveihier, J. Traté d′anatomie pathologique genéràle; Bulletins de la Société d'anthropologie de Paris, Ed.; Billièr: Paris, France, 1862; p. 48.
[29]
MacDonald, W.; Rubin, C. Gastric biopsy: A critical evaluation. Gastroenterology 1967, 53, 143–170.
[30]
Edwards, F.; Coghill, N. Aetiological factors in chronic atrophic gastritis. Br. Med. J. 1966, ii, 1400–1415.
[31]
Warren, J.; Marshall, B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, I, 1273–1275.
[32]
Correa, P. A human model of gastric carcinogenesis. Cancer Res. 1988, 48, 1319–1326.
[33]
Oh, J.D.; Kling-Backhed, H.; Giannakis, M.; Engstrand, L.G.; Gordon, J.I. Interactions between gastric epithelial stem cells and Helicobacter pylori in the setting of chronic atrophic gastritis. Curr. Opin. Microbiol. 2006, 9, 21–27, doi:10.1016/j.mib.2005.12.013.
[34]
Dixon, M.F.; Genta, R.M.; Yardley, J.H.; Correa, P. Classification and grading of gastritis: The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am. J. Surg. Pathol. 1996, 20, 1161–1181.
[35]
Giannella, R.; Broitman, S.; Zamcheck, N. Gastric acid barrier to ingested micro-organisms in man: Studies in vivo and in vitro. Gut 1972, 13, 251–256, doi:10.1136/gut.13.4.251.
[36]
Rubio, C.A.; Jaramillo, E.; Suzuki, G.; Lagergren, P.; Nesi, G. Antralization of the gastric mucosa of the incisura angularis an its gastrin expression. Int. J. Clin. Exp. Pathol. 2009, 2, 65–70.
[37]
Nakajima, S.; Nishiyama, Y.; Yamaoka, M.; Yasuoka, T.; Cho, E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years. J. Gastroenterol. Hepatol. 2010, 25, S99–S110, doi:10.1111/j.1440-1746.2009.06214.x.
[38]
Campbell, D.; Warren, B.; Thomas, J.; Figura, N.; Telford, J.; Sullivan, P. The African enigma: Low prevalence of gastric atrophy, high prevalence of chronic inflammation in West African adults and children. Helicobacter 2001, 6, 263–267, doi:10.1046/j.1083-4389.2001.00047.x.
[39]
Graham, D.Y.; Lu, H.; Yamaoka, Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: Facts or medical myths. J. Dig. Dis. 2009, 10, 77–84, doi:10.1111/j.1751-2980.2009.00368.x.
[40]
Saieva, C.; Rubio, C.A.; Nesi, G.; Zini, E.; Filomena, A. Classification of gastritis in first-degree relatives of patients with gastric cancer in a high cancer-risk area in Italy. Anticancer Res. 2012, 32, 1711–1716.
[41]
Torbenson, M.; Abraham, S.C.; Boitnott, J.; Yardley, J.H.; Wu, T. Autoimmune gastritis: Distinct histological and immuno-histochemical findings before complete loss of oxyntic glands. Mod. Pathol. 2002, 15, 102–109, doi:10.1038/modpathol.3880499.
[42]
Petersson, F.; Borch, K.; Franzén, E. Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand. J. Gastroenterol. 2002, 37, 262–266, doi:10.1080/003655202317284156.
[43]
Rubio, C.A.; Kaufeldt, A. Paucity of synaptophysin-expressing cells in Barrett’s mucosa. Histopathology 2013, 63, 208–216, doi:10.1111/his.12168.
[44]
Guerre, J.; Vedel, G.; Gaudric, M.; Paul, G.; Cornuau, J. Bacterial flora in gastric juice taken at endoscopy in 93 normal subjects. Pathol. Biol. 1986, 34, 57–60.
[45]
Monstein, H.J.; Tiveljung, A.; Kraft, C.H.; Borch, K.; Jonasson, J. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J. Med. Microbiol. 2000, 49, 817–822.
[46]
Bik, E.M.; Eckburg, P.B.; Gill, S.R.; Nelson, K.E.; Purdom, E.A. Molecular analysis of the bacterial microbiota in the human stomach. Proc. Natl. Acad. Sci. USA 2006, 103, 732–737.
[47]
Li, X.X.; Wong, G.L.; To, K.F.; Wong, V.W.; Lai, L.H. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-Inflammatory drug use. PLoS ONE 2009, 4, e7985.
[48]
Shen, B.; Porter, E.M.; Reynoso, E.; Shen, C.; Ghosh, D.; Connor, J.T.; Drazba, J.; Rho, H.K.; Gramlich, T.L.; Li, R.; et al. Human defensin 5 expression in intestinal metaplasia of the upper gastrointestinal tract. J. Clin. Pathol. 2005, 58, 687–691, doi:10.1136/jcp.2004.022426.
[49]
Rubio, C.A. My approach to reporting a gastric biopsy. J. Clin. Pathol. 2007, 60, 160–166, doi:10.1136/jcp.2006.039008.
[50]
Shousha, S.; el-Sherif, A.M.; el-Guneid, A.; Arnaout, A.H. Helicobacter pylori and intestinal metaplasia: Comparison between British and Yemeni patients. Am. J. Gastroenterol. 1993, 88, 1373–1376.
[51]
Rubio, C.A.; Kato, Y.; Sugano, H.; Kitagawa, T. Intestinal metaplasia of the stomach in Swedish and Japanese patients without ulcers or carcinoma. Jpn. J. Cancer Res. 1987, 78, 467–472.
[52]
Rubio, C.A.; Jessurum, J.; Kato, Y. Low frequency of intestinal metaplasia in gastric biopsies from Mexican patients: A comparison with Japanese and Swedish patients. Jpn. J. Cancer Res. 1992, 83, 491–494, doi:10.1111/j.1349-7006.1992.tb01954.x.
[53]
Shand, A.; Taylor, A.; Banerjee, M.; Lessels, A.; Coia, J.; Clark, C.; Haites, N.; Ghosh, S. Gastric fundic gland polyps in south-east Scotland: Absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2002, 17, 1161–1164, doi:10.1046/j.1440-1746.2002.02863.x.
[54]
Rubio, C.A. Plugs clog the glandular outlets in fundic gland polyps. Int. J. Clin. Exp. Pathol. 2009, 3, 69–74.
Dewar, D.H.; Ciclitira, P.J. Clinical features and diagnosis of celiac disease. Gastroenterology 2005, 128, S19–S24, doi:10.1053/j.gastro.2005.02.010.
[57]
Ivarsson, A.; H？gberg, L.; Stenhammar, L.; Swedish Childhood Coeliac Disease Working Group. The swedish childhood coeliac disease working group after 20 years: History and future. Acta Paediatr. 2010, 99, 1429–1431, doi:10.1111/j.1651-2227.2010.01832.x.
[58]
Myléus, A.; Ivarsson, A.; Webb, C.; Danielsson, L.; Hernell, O.; H？gberg, L.; Karlsson, E.; Lagerqvist, C.; Norstr？m, F.; Rosén, A.; et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J. Pediatr. Gastroenterol. Nutr. 2009, 49, 170–176, doi:10.1097/MPG.0b013e31818c52cc.
[59]
Sánchez, E.; Donat, E.; Ribes-Koninckx, C.; Calabuig, M.; Sanz, Y. Intestinal Bacteroides species associated with coeliac disease. J. Clin. Pathol. 2010, 63, 1105–1111, doi:10.1136/jcp.2010.076950.
[60]
Schippa, S.; Lebba, V.; Barbato, M.; di Nardo, G.; Totino, V.; Checchi, M.P.; Longhi, C.; Maiella, G.; Cucchiara, S.; Conte, M.P. A distinctive “microbial signature” in celiac pediatric patients. BMC Microbiol. 2010, 10, 175–179, doi:10.1186/1471-2180-10-175.
[61]
Forsberg, G.; Fahlgren, A.; H？rstedt, P.; Hammarstr？m, S.; Hernell, O.; Hammarstr？m, M.L. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am. J. Gastroenterol. 2004, 99, 894–904, doi:10.1111/j.1572-0241.2004.04157.x.
[62]
Ou, G.; Hedberg, M.; H？rstedt, P.; Baranov, V.; Forsberg, G.; Drobni, M.; Sandstr？m, O.; Hammarstr？m, S. Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am. J. Gastroenterol. 2009, 104, 3058–3067, doi:10.1038/ajg.2009.524.
[63]
Rubio, C.A. Signaling pathways, gene regulation and duodenal neoplasiasChapter 6. In Signaling, Gene Regulation and Cancer; Singh, S.R., Ed.; Nova Science Publishers, Inc.: Haupauge, NY, USA, 2013; pp. 83–110.
[64]
Lindstr？m, C.G. “Collagenous colitis” with watery diarrhoea: A new entity? Pathol Eur. 1976, 11, 87–89.
[65]
Giardiello, F.M.; Lazenby, A.J.; Bayless, T.M.; Levine, E.J.; Bias, W.B.; Ladenson, P.W.; Yardley, J.H. Lymphocytic (microscopic) colitis. Clinico-pathologic study of 18 patients and comparison to collagenous colitis. Dig. Dis. Sci. 1989, 34, 1730–1738, doi:10.1007/BF01540051.
[66]
Wickbom, A.; Bohr, J.; Eriksson, S.; Udumyan, R.; Nyhlin, N.; Tysk, C. Stable incidence of collagenous colitis and lymphocytic colitis in ？rebro, Sweden, 1999–2008: A continuous epidemiologic study. Inflamm. Bowel Dis. 2013, 19, 2387–2393, doi:10.1097/MIB.0b013e31829ed8cd.
[67]
Gustafsson, R.J.; Ohlsson, B.; Benoni, C.; Jeppsson, B.; Olsson, C. Mucosa-associated bacteria in two middle-aged women diagnosed with collagenous colitis. World J. Gastroenterol. 2012, 18, 1628–1634, doi:10.3748/wjg.v18.i14.1628.
[68]
Helal, T.E.; Ahmed, N.S.; el Fotoh, O.A. Lymphocytic colitis: A clue to bacterial etiology. World J. Gastroenterol. 2005, 11, 7266–7271.
[69]
Rubio, C.A.; Hubbard, G.B. Chronic colitis in baboons: Similarities with chronic colitis in humans. In Vivo 2001, 15, 109–116.
[70]
Khalil, N.A.; Walton, G.E.; Gibson, G.R.; Tuohy, K.M.; Andrews, S.C. In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet. Int. J. Food Sci. Nutr. 2014. in press.
[71]
Kumari, R.; Ahuja, V.; Paul, J. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. World J. Gastroenterol. 2013, 19, 3404–3408, doi:10.3748/wjg.v19.i22.3404.
[72]
Varela, E.; Manichanh, C.; Gallart, M.; Torrejón, A.; Borruel, N.; Casellas, F.; Guarner, F.; Antolin, M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 2013, 38, 151–156, doi:10.1111/apt.12365.
[73]
Pilarczyk-Zurek, M.; Chmielarczyk, A.; Gosiewski, T.; Tomusiak, A.; Adamski, P.; Zwolinska-Wcislo, M.; Mach, T.; Heczko, P.; Strus, M. Possible role of Escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol. 2013, doi:10.1186/1471-230X-13-61.
[74]
Yukawa, T.; Ohkusa, T.; Shibuya, T.; Tsukinaga, S.; Mitobe, J.; Takakura, K.; Takahara, A.; Odahara, S.; Tajiri, H. Nested culture method improves detection of Fusobacterium from stool in patients with ulcerative colitis. Jpn. J. Infect. Dis. 2013, 66, 109–111, doi:10.7883/yoken.66.109.
[75]
Kabeerdoss, J.; Sankaran, V.; Pugazhendhi, S.; Ramakrishna, B.S. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: A case-control study in India. BMC Gastroenterol. 2013, 13, 20–26, doi:10.1186/1471-230X-13-20.
[76]
Ga？ecka, M.; Szachta, P.; Bartnicka, A.; ？ykowska-Szuber, L.; Eder, P.; Schwiertz, A. Faecalibacterium prausnitzii and Crohn’s disease—Is there any connection? Pol. J. Microbiol. 2013, 62, 91–95.
[77]
Kale-Pradhan, P.B.; Zhao, J.; Palmer, J.; Wilhelm, S.M. The role of antimicrobials in Crohn’s disease. Expert. Rev. Gastroenterol. Hepatol. 2013, 7, 281–288, doi:10.1586/egh.13.6.
[78]
Nickerson, K.; McDonald, C. Crohn’s disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin. PLoS One 2012, 7, e52132, doi:10.1371/journal.pone.0052132.
[79]
Erickson, A.; Cantarel, B.; Lamendella, R.; Darzi, Y.; Mongodin, E.; Pan, C.; Shah, M.; Halfvarson, J.; Jansson, J.K. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn’s disease. PLoS One 2012, 7, e49138, doi:10.1371/journal.pone.0049138.
[80]
Jostins, L.; Ripke, S.; Weersma, R.K.; Duerr, R.H.; McGovern, D.P.; Hui, K.Y.; Lee, J.C.; Schumm, L.; Sharma, Y.; Anderson, C.; et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119–124, doi:10.1038/nature11582.
[81]
Shanahan, F. The microbiota in inflammatory bowel disease: Friend, bystander, and sometime-villain. Nutr. Rev. 2012, 70, S31–S37, doi:10.1111/j.1753-4887.2012.00502.x.
[82]
Muriel-Galet, V.; Talbert, J.N.; Hernandez-Munoz, P.; Gavara, R.; Goddard, J.M. Covalent immobilization of lysozyme on ethylene vinyl alcohol films for nonmigrating antimicrobial packaging applications. J. Agric. Food Chem. 2013, 61, 6720–6727, doi:10.1021/jf401818u.
[83]
Ibrahim, H.R.; Imazato, K.; Ono, H. Human lysozyme possesses novel antimicrobial peptides within its N-terminal domain that target bacterial respiration. J. Agric. Food Chem. 2011, 59, 10336–10345, doi:10.1021/jf2020396.
[84]
Oliver, W.T.; Wells, J.E. Lysozyme as an alternative to antibiotics improves growth performance and small intestinal morphology in nursery pigs. J. Anim. Sci. 2013, 91, 3129–3136, doi:10.2527/jas.2012-5782.
[85]
Teneback, C.; Scanlon, T.; Wargo, M.; Bement, J.; Griswold, K.; Leclair, L.W. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob. Agents Chemother. 2013, 57, 5559–5564, doi:10.1128/AAC.00500-13.
[86]
Pridgeon, J.W.; Klesius, P.H.; Dominowski, P.J.; Yancey, R.J.; Kievit, M.S. Chicken-type lysozyme in channel catfish: Expression analysis, lysozyme activity, and efficacy as immunostimulant against Aeromonas hydrophila infection. Fish Shellfish Immunol. 2013, 35, 680–688, doi:10.1016/j.fsi.2013.05.018.
[87]
Cegielska-Radziejewska, R.; Szablewski, T. Effect of modified lysozyme on the microflora and sensory attributes of ground pork. J. Food Prot. 2013, 76, 338–342, doi:10.4315/0362-028X.JFP-12-075.
[88]
Lamppa, J.W.; Tanyos, S.A.; Griswold, K.E. Engineering Escherichia coli for soluble expression and single step purification of active human lysozyme. J. Biotechnol. 2013, 164, 1–8, doi:10.1016/j.jbiotec.2012.11.007.
[89]
Rosu, V.; Bandino, E.; Cossu, A. Unraveling the transcriptional regulatory networks associated to mycobacterial cell wall defective form induction by glycine and lysozyme treatment. Microbiol. Res. 2013, 168, 153–164, doi:10.1016/j.micres.2012.10.002.
